ArticleImmunity2013
Anthracyclines induce DNA damage response-mediated protection against severe sepsis.
Article in Immunity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05033808 (Epirubicin for the Treatment of Sepsis & Septic Shock), which is not on this map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Epirubicin for the Treatment of Sepsis & Septic Shock
Who cites it
88 citing papers in PubMed, 140 citations in OpenAlex.
- Immune responses and immunomodulation in sepsis: a call for identifying treatable mechanisms.Intensive care medicine · 2026Article
- Functional Genomics: Principles and Methods.Advances in experimental medicine and biology · 2026Review
- Combination of machine learning and protein‑protein interaction network established one ATM‑DPP4‑TXN ferroptotic diagnostic model with experimental validation.Molecular medicine reports · 2025Article
- Biological and clinical implications of a model of surveillance immunity.The Journal of clinical investigation · 2025Review
- Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair.Signal transduction and targeted therapy · 2025Article
- ATM in immunobiology: From lymphocyte development to cancer immunotherapy.Translational oncology · 2025Review
- The interplay between probiotics and host autophagy: mechanisms of action and emerging insights.Autophagy · 2025Review
- Losmapimod ameliorates doxorubicin-induced cardiotoxicity through attenuating senescence and inflammatory pathways.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- The cytochrome P4501A1 (CYP1A1) inhibitor bergamottin enhances host tolerance to multidrug-resistant Vibrio vulnificus infection.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2024Article
- Immunomodulatory Effects and Protection in Sepsis by the Antibiotic Moxifloxacin.Antibiotics (Basel, Switzerland) · 2024Article
- Article
- Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies.The Lancet. Respiratory medicine · 2024Review
- PMI-controlled mannose metabolism and glycosylation determines tissue tolerance and virus fitness.Nature communications · 2024Article
- Prognostic stratification of sepsis through DNA damage response based RiskScore system: insights from single-cell RNA-sequencing and transcriptomic profiling.Frontiers in immunology · 2024Article
- Targeting the host response in sepsis: current approaches and future evidence.Critical care (London, England) · 2023Review
- Update on persistent acute kidney injury in critical illnesses.Clinical kidney journal · 2023Review
- What's new in intensive care: disease tolerance.Intensive care medicine · 2023Article
- Pharmacological modulators of epithelial immunity uncovered by synthetic genetic tracing of SARS-CoV-2 infection responses.Science advances · 2023Article
- Starvation Protects Hepatocytes from Inflammatory Damage through Paradoxical mTORC1 Signaling.Cells · 2023Article
- Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
28 authors at 9 institutions in 3 countries.
Funding
Abstract
Severe sepsis remains a poorly understood systemic inflammatory condition with high mortality rates and limited therapeutic options in addition to organ support measures. Here we show that the clinically approved group of anthracyclines acts therapeutically at a low dose regimen to confer robust protection against severe sepsis in mice. This salutary effect is strictly dependent on the activation of DNA damage response and autophagy pathways in the lung, as demonstrated by deletion of the ataxia telangiectasia mutated (Atm) or the autophagy-related protein 7 (Atg7) specifically in this organ. The protective effect of anthracyclines occurs irrespectively of pathogen burden, conferring disease tolerance to severe sepsis. These findings demonstrate that DNA damage responses, including the ATM and Fanconi Anemia pathways, are important modulators of immune responses and might be exploited to confer protection to inflammation-driven conditions, including severe sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.